جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

مقالوصول مفتوح2026

VG-RETFound: a hybrid retinal AI framework for early vision impairment screening through vessel-graph learning and cross-modal fusion

Frontiers in Medicine · مجلد 13 · 1905129-1905129

Introduction: Vision impairment caused by retinal diseases stands out as one of the significant sources of irreversible blindness, highlighting the importance of developing robust automated screening tools to detect eye diseases at an early stage. Despite the promising results of recent deep learning approaches to the automatic classification of retinal images, most existing solutions focus on image-based representations and do not consider the importance of vascular topology. To overcome the limitations, this study proposes VG-RETFound - a hybrid framework based on a retinal foundation model and graph-based vascular-topology modeling that can be used to classify multiple retinal categories and detect vision impairment. Methods: The authors use RETFound-a retinal foundation model-pretrained on a vast number of retinal images, as well as the Graph Attention Network (GAT), to learn vascular topology features by representing retinal vessels as graphs. The presented approach employs a cross-modal multi-head attention fusion method to integrate features from both modalities in real time. To evaluate the efficiency of VG-RETFound, experiments were conducted using the RFMiD and ODIR-5 K datasets for model training and testing across six retinal categories: Normal, Diabetic Retinopathy, Pathological Myopia, Age-related Macular Degeneration, Hypertensive Retinopathy, and Other Retinal Diseases. Results: The accuracy of 96.39%, F1-score of 95.84%, MCC of 94.87%, and Kappa of 94.71% were attained on an internal test dataset, while cross-dataset external validation on the BRSET dataset revealed accuracy of 94.81%, F1-score of 94.25%, MCC of 93.09%, and Kappa of 92.94%. Discussion: These findings demonstrate that integrating retinal foundation models with anatomically informed vessel-topology learning significantly improves classification accuracy, interpretability, and generalization, highlighting the potential of VG-RETFound as a tool for large-scale vision impairment. screening and retinal disease diagnosis.

retinal disease classificationRETFoundgraph attention networksvascular topology
مقالمفتوح (مستودع)2026

New Chromene Derivatives as Promising VEGFR‐2 Inhibitors: Experimental Cytotoxicity and Comprehensive Computational Characterization

Archiv der Pharmazie · مجلد 359 (9) · e70328-e70328

ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.

chromene derivativesVEGFR-2 inhibitorsantiproliferative activitycancer cell lines
مراجعةوصول مفتوح2026

Oteseconazole for acute and recurrent vulvovaginal candidiasis: A systematic review, meta-analysis, and trial sequential analysis of randomized trials

Journal of International Medical Research · مجلد 54 (9) · 3000605261476919-3000605261476919

ObjectivesVulvovaginal candidiasis and its recurrent vulvovaginal candidiasis form place a significant burden on women worldwide. However, treatment options remain limited. Oteseconazole, a first-in-class tetrazole CYP51 inhibitor that received Food and Drug Administration approval for recurrent vulvovaginal candidiasis in 2022, has not yet had its comparative efficacy against fluconazole in acute vulvovaginal candidiasis systematically synthesized. In addition, the full scope of evidence for its maintenance use has not been formally synthesized. Using a dual-Population-Intervention-Comparator-Outcome (PICO) framework, this systematic review and meta-analysis aimed to: (a) evaluate whether oteseconazole provides superior efficacy to fluconazole in acute vulvovaginal candidiasis; (b) comprehensively synthesize maintenance efficacy and safety outcomes in recurrent vulvovaginal candidiasis; and (c) assess the certainty and sufficiency of the available evidence using Grading of Recommendations Assessment, Development, and Evaluation and trial sequential analysis.MethodsThis systematic review and meta-analysis was prospectively registered with PROSPERO (registration number: CRD420261331936). A systematic search of PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov was conducted without date or language restrictions. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Meta-analyses were performed using random-effects models with restricted maximum likelihood estimation and Hartung-Knapp-Sidik-Jonkman correction.ResultsA total of five unique randomized controlled trials (six PICO-level inclusions) were included, enrolling 596 participants across PICO 1 and 1090 across PICO 2. In acute vulvovaginal candidiasis (PICO 1, two trials, n = 361), oteseconazole was associated with a significantly higher therapeutic cure rate (composite clinical and mycological cure) at day 28 than fluconazole (risk ratio = 1.39, 95% confidence interval: 1.13 to 1.71; p = 0.002). Significant improvements were also observed in clinical cure at day 28 (risk ratio = 1.28, 95% confidence interval: 1.09 to 1.51; p = 0.003) and mycological cure at both day 14 (risk ratio = 1.24, 95% confidence interval: 1.09 to 1.41; p = 0.001) and day 28 (risk ratio = 1.38, 95% confidence interval: 1.20 to 1.58; p < 0.001). In recurrent vulvovaginal candidiasis prevention (PICO 2, four trials, n = 959), oteseconazole significantly reduced culture-confirmed recurrence at weeks 48-50 (risk ratio = 0.13, 95% confidence interval: 0.09 to 0.19) and week 24 (risk ratio = 0.10, 95% confidence interval: 0.07 to 0.15) and substantially prolonged the time to first recurrence (hazard ratio = 0.09, 95% confidence interval: 0.05 to 0.14), all with zero heterogeneity. Furthermore, trial sequential analysis confirmed that the cumulative evidence surpassed the required information size for both recurrence time points. Safety outcomes were comparable between groups in both settings.ConclusionsIn patients with recurrent vulvovaginal candidiasis, oteseconazole demonstrated favorable outcomes by significantly reducing recurrent infections while maintaining a comparable safety profile, supporting its use as a maintenance regimen. However, the evidence supporting its role in acute vulvovaginal candidiasis remains limited.

oteseconazolerecurrent vulvovaginal candidiasisfluconazoleCYP51 inhibitors
مقالمفتوح (مستودع)2026

Unraveling the Anti‐Arthritic Potential of Bioactive Compounds From Melaleuca alternifolia Oil: Integrated In Vivo, Molecular Docking, and Network Pharmacology Insights

Food Science & Nutrition · مجلد 14 (9) · e72328-e72328

ABSTRACT Rheumatoid arthritis (RA) is a chronic inflammatory condition that affects millions of people globally, often leading to morbidity. Recent research highlights the potential of natural products in managing arthritis symptoms and modifying disease progression. Among these, Melaleuca alternifolia oil (MAO) has emerged as a promising therapeutic option due to its anti‐inflammatory and analgesic properties. A total of 36 Sprague–Dawley rats weighing between 200 and 220 g were divided into six groups ( n = 6). On day 0, arthritis was induced by CFA. On day 8, treatment started and lasted till day 28. Paw edema and arthritic score were measured. Moreover, hematological, histological, and biochemical parameters were evaluated. The mRNA expression levels of anti‐inflammatory cytokine IL‐4 and pro‐inflammatory cytokines such as TNF‐α, IL‐6, NF‐κB, and IL‐1β were measured using real‐time polymerase chain reaction (qPCR). ELISA was used to detect PGE2 levels. Network pharmacology was used to evaluate the hub genes between the phytocompounds and rheumatoid arthritis. Molecular docking and scoring calculations were done for the top matched hub genes for moderate confirmations between phytocompounds and targets. GC–MS analysis was also performed to identify potential anti‐inflammatory constituents present in the plant oil. Treatment with MAO effectively reduced paw edema and swelling. Histopathological examinations demonstrated significant improvement in the treatment groups. Biochemical parameters such as creatinine, urea, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) did not significantly alter, and hematological parameters such as red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb), and platelet count were restored in the treated group. The mRNA expression of anti‐inflammatory cytokines, including IL‐4, was upregulated, and pro‐inflammatory biomarkers such as TNF‐α, IL‐1β, IL‐6, and NF‐κB were significantly downregulated in the arthritic control group. Furthermore, treatment with MAO significantly reduced PGE2 levels. Network pharmacology indicated the hub genes and several biological processes, molecular functions, cellular components, and KEGG pathways that are involved in rheumatoid arthritis. Molecular docking was performed against hub genes such as AKT1, BCL‐2, MAPK3, and MMP9 that are involved in various pro‐inflammatory cytokine formation and pathophysiology of rheumatoid arthritis. GC–MS analysis of the plant's oil revealed the presence of numerous anti‐inflammatory and antirheumatic phytochemicals. MAO possesses considerable anti‐arthritic properties by downregulating pro‐inflammatory biomarkers such as IL‐1β, NF‐κB, IL‐6, TNF‐α, and upregulating anti‐inflammatory IL‐4. Further investigations are needed to explore its potential as a natural therapeutic option for treating RA.

tea tree oilrheumatoid arthritisanti-inflammatory activityCFA-induced arthritis
مقالوصول مغلق2026

Preventive effects of quercetin and N-acetylcysteine, alone and combined, against acetaminophen-induced hepatotoxicity in rats: associations with COX-2/TGF-β1 and Nrf2/HO-1 mRNA expression

Toxicology Research · مجلد 15 (5)

Abstract This study evaluated the preventive effects of quercetin (QR) and N-acetylcysteine (NAC), alone or combined, in a rat model of acute acetaminophen (APAP)-induced hepatotoxicity. Twenty-five male rats were allocated to five groups (n = 5): control, APAP, NAC + APAP, QR + APAP, and NAC + QR + APAP. NAC (150 mg/kg) and/or QR (50 mg/kg) were administered orally for 7 days before a single oral APAP dose (2 g/kg). Serum liver-function indices, lipid profile, circulating TNF-α and IL-6, hepatic oxidative-status indices, hepatic COX-2, TGF-β1, Nrf2, and HO-1 mRNA abundance, histopathology, and IL-1β immunohistochemistry were assessed. APAP increased ALT, AST, triglycerides, total cholesterol, TNF-α, IL-6, and hepatic MDA, while decreasing total protein, albumin, HDL-C, GSH, CAT, SOD, and GPx. It also increased COX-2 and TGF-β1 transcripts and decreased Nrf2 and HO-1 transcripts. Pretreatment with NAC or QR partially attenuated these changes, whereas their combination generally produced values closer to control. The combined regimen also reduced histological injury and IL-1β immunoreactivity relative to APAP. These findings support a preventive association between combined NAC/QR exposure and improved redox and inflammatory indices. Because protein abundance, Nrf2 nuclear translocation, treatment after injury, and treatment-only controls were not evaluated, the data do not establish pathway activation, pharmacological synergy, or therapeutic efficacy after established overdose.

quercetinN-acetylcysteineacetaminophen hepatotoxicitydrug-induced liver injury
مراجعةوصول مفتوح2026

Neuromuscular Electrical Stimulation for Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials Evaluating Pain, Disability, Muscle Strength, and Functional Performance

Orthopedic Reviews · مجلد 18 · 168252-168252

Background: Neuromuscular electrical stimulation (NMES) is widely used in the rehabilitation of knee osteoarthritis (KOA) to improve quadriceps activation and counteract arthrogenic muscle inhibition. However, randomized controlled trials (RCTs) have reported inconsistent findings, and the overall clinical effectiveness of NMES across key patient outcomes remains uncertain. Objective: To evaluate the effects of NMES, administered alone or in combination with exercise, on pain, self-reported disability, quadriceps muscle strength, and functional performance in adults with KOA, and to explore whether treatment effects differ according to comparator intervention. Methods: A systematic review and meta-analysis of RCTs was conducted according to PRISMA 2020. PubMed/MEDLINE, Embase, Scopus, Web of Science, and CENTRAL were searched from inception to April 20, 2026. Random-effects meta-analyses were performed using restricted maximum likelihood estimation. Prespecified subgroup and sensitivity analyses were undertaken, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Eight unique RCTs (10 publications) were included. Overall, NMES did not significantly improve pain, self-reported disability, quadriceps strength, or six-minute walk distance compared with pooled comparator interventions. A significant improvement was observed for Timed Up and Go performance, although this estimate was largely driven by a single trial. Prespecified subgroup analyses demonstrated that treatment effects differed according to comparator intervention. NMES combined with exercise resulted in greater pain reduction than exercise alone, whereas no consistent advantage was observed when NMES was compared with alternative conservative interventions. Most trials were judged to have low risk of bias or some concerns. Conclusions: NMES does not appear to provide consistent clinical benefits across all rehabilitation settings for KOA. Rather, its effectiveness depends on the therapeutic context in which it is delivered, with the greatest benefit observed when used as an adjunct to structured exercise rather than as a stand-alone intervention. Larger, methodologically rigorous RCTs using standardized stimulation protocols are required to define the patients most likely to benefit.

neuromuscular electrical stimulationknee osteoarthritisquadriceps strengtharthrogenic muscle inhibition
مقالوصول مفتوح2026

Protective effect of hesperetin against myelosuppression and splenic inflammation via modulating TLR4/MYD88/NF-κB signaling: molecular docking and experimental validation

Frontiers in Pharmacology · مجلد 17 · 1826774-1826774

Introduction: Myelotoxicity is a common adverse effect of vincristine and other chemotherapeutic drugs. Hesperetin is a bioactive flavanone with anti-inflammatory activity. This study was planned to examine the hesperetin protecting effect against vincristine induced myelosuppression and splenic inflammation in mice and test whether this effect is mediated through the suppression of Toll-like receptor 4 (TLR4)/myeloid differentiation primary response-88 (MYD88)/nuclear factor-kappa B (NF-κB) signaling pathways. Methods: Bioinformatics tools were used to establish the rationale of the study and molecular docking defined the potential binding of hesperetin to TLR4. Mice were allocated into different experimental groups: Group 1: was the saline mice, Group 2; mice were injected with vincristine (0.1 mg/kg, i. p) for 5 days per week, Group 3; mice received vincristine (as in Group 2) plus hesperetin (100 mg/kg, p. o.) and Group 4; mice received hesperetin (100 mg/kg, p. o.) only; the experiment continued for 2 weeks. Results: 9/L in the saline group, p less than 0.05) and bone marrow hypocellularity (dropped to ∼30-40% compared to 95%-100% in the saline group). The spleens showed white pulp lymphoid depletion, red pulp mild hypocellularity, greater immunostaining for MYD88, and greater content for TLR4, NF-κB, MYD88, TNF-α and IL-1β proteins. Results of molecular docking showed that hesperetin is an interesting complementarity with the TLR4/MD2 interface which was a good rationale for the experimental validation. The mouse experiment showed that hesperetin prevented the decrease hematological parameters, enhanced the bone marrow cellularity to 80%-90%, and the splenic architecture. Hesperetin further inhibited the increases in the target proteins (TLR4, NF-κB, MYD88, TNF-α and IL-1β) significantly. Discussion: The present data documents the novel role of hesperetin in mitigating myelotoxicity of vincristine through modulation of TLR4/MYD88/NF-κB signaling and a direct binding to TLR4 was proposed by molecular docking. This highlights possible usefulness of this combination after adequate clinical studies.

hesperetinvincristinemyelosuppressionsplenic inflammation
مقالمفتوح (مستودع)2026

N ‐Acetyl Cysteine Mitigates d ‐Ribose‐Induced Protein Glycation and Aggregation Through Multiple Protective Mechanisms

IUBMB Life · مجلد 78 (9) · e70126-e70126

Advanced glycation end-products (AGEs) arise from non-enzymatic reactions between reducing sugars and proteins, contributing to oxidative stress and metabolic dysfunction. Excessive AGE accumulation is implicated in chronic diabetic complications and may also be relevant to acute metabolic disturbances encountered in emergency medicine. N-acetylcysteine (NAC), a naturally occurring antioxidant found in Allium species, has demonstrated potential to attenuate oxidative and glycation-mediated damage. The effect of NAC on d-ribose-induced glycation of bovine serum albumin (BSA) was investigated using multiple physicochemical and spectroscopic techniques. AGE formation was assessed by measuring hyperchromicity, early glycation products (ketoamines), carbonyl content, hydroxymethylfurfural (HMF) levels, and fluorescent AGEs. The protective effect of NAC was further evaluated by determining free lysine and arginine contents. Protein aggregation and conformational changes were analyzed using Congo Red binding and fluorescence assays including thioflavin-T and 1-anilinonaphthalene-8-sulfonic acid. NAC significantly inhibited d-ribose-mediated glycation of BSA in a concentration-dependent manner. Treatment with NAC resulted in reduced hyperchromicity, decreased ketoamine formation, and lower carbonyl, HMF, and fluorescent AGE levels. NAC preserved protein integrity by maintaining higher free lysine and arginine contents. In addition, NAC markedly attenuated glycation-induced protein aggregation, as evidenced by reduced Congo Red binding and diminished thioflavin-T and ANS fluorescence, with maximal protection observed at 300 μM. NAC exhibits pronounced anti-glycation and anti-aggregation effects by limiting oxidative stress and glycation-mediated protein modification. These findings demonstrate that NAC effectively attenuates d-ribose-induced glycation and protein aggregation in vitro and provide mechanistic insights into its anti-glycation properties through multiple complementary biochemical mechanisms. Further studies are warranted to evaluate its biological relevance in more complex experimental models.

N-acetylcysteineadvanced glycation end productsprotein glycationprotein aggregation
مقالمفتوح (مستودع)2026

A Topological and Spatial Analysis of FDA‐Approved Drugs, Blood‐Brain Barrier Permeants, Natural Products, and Metabolites

ChemMedChem · مجلد 21 (17) · e70462-e70462

In this study, we present a comprehensive structural analysis of four distinct chemical libraries: FDA‐approved drugs, blood‐brain barrier (BBB) permeable agents, natural products (UNPDA), and human metabolites. Our multidimensional profiling reveals fundamental divergences in molecular architecture. While synthetic drugs (FDA) and CNS‐active agents (BBB) follow continuous, Gaussian‐like distributions for carbon hybridization, natural products exhibit biosynthetic quantization, discrete, high‐intensity abundance spikes at C19 and C30, corresponding to steroid and triterpene scaffolds. Stereochemical analysis identifies a chirality‐structure lock in natural products, where stereoisomer density peaks significantly at these same integers (Avg. 3.53 isomers/mol), a complexity feature absent in the diffuse distribution of synthetic libraries. Topologically, we identify hyper‐globularity as a distinct signature for CNS permeability. Radial distribution function (RDF) analysis demonstrates that BBB agents possess a highly compressed aliphatic core, packing 93.2% of their sp 3 mass within a 3 Å radius, compared to 84.4% for general FDA therapeutics. Furthermore, elemental profiling reveals a heteroatom gap: synthetic drugs exhibit a high electronegative atom‐to‐carbon ratio (0.43), whereas BBB agents (0.33) converge with the lipophilic profile of natural products (0.32), suggesting that CNS penetration requires a biomimetic reduction in polarity. These findings establish new quantitative metrics for designing neuro‐compatible and biomimetic pharmacophores.

blood-brain barrier permeabilitynatural productshuman metabolitesFDA-approved drugs